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Abstract The analysis of cerebrospinal fluid (CSF) is an
important tool for the diagnosis of neurological diseases.
However, there is limited knowledge about the represen-
tativity of a single oligoclonal band (OCB) analysis for a
neurological disease during its clinical course. In this
study, we analyzed the presence of OCB in the CSF of
patients who underwent lumbar puncture more than once.
We retrospectively analyzed anonymized data from serial
17,002 CSF analyses done in the CSF laboratory of the
Department of Neurology, University Hospital Zurich. We
included cases with documented diagnosis in whom OCB
were determined more than once. We included 144
patients. The median time span between the first and sec-
ond OCB analysis was 274 days (range, 1–3,533 days).
The result of the second OCB analysis was identical in 109
cases, and different in 35 (24 %). Twenty-five patients
acquired and ten patients lost OCB over time. Three of 24
MS patients did not show OCB at the first CSF analysis,
but in the second. In the entire group, newly occurring
OCB were often associated with new symptoms or occur-
red after the acute phase of CNS infectious diseases, sup-
posedly as a consequence of the immune reaction. A loss of
OCB was often associated with remissions from diseases,
e.g., during effective treatment. In patients with neurolog-
ical diseases, both initially positive and negative OCB
results may change over time, which often parallels the
clinical condition. Such variability must be taken into
account for the interpretation of OCB results.
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Introduction
The primary function of cerebrospinal fluid (CSF) is pro-
tecting the central nervous system (CNS) from mechanical
injury. Moreover, it is important for homeostatic regula-
tion, helps in maintaining intracerebral pressure at a con-
stant level, circulates nutrients, and rinses waste products
from the brain parenchyma. In humans, the majority of
CSF originates from the four choroid plexus in the ven-
tricles, from parenchyma of the brain and of the spinal
cord, and from ependymal lining of the ventricles [1, 2].
CSF is constantly produced and mainly drained through
cisternae, subarachnoid space, and arachnoid villi into the
venous blood. The transfer of proteins, such as albumin,
antibodies, or complement, from blood into CSF follows
passive diffusion as a function of molecular size. Restric-
tion of this transfer from blood into the CSF is called the
blood–CSF fluid barrier [3, 4]. While leukocytes can cross
vessel walls to reach the perivascular space (PVS) as part
of normal immune surveillance, their progression across
the glia limitans into the brain parenchyma depends on
perivascular antigen recognition, inducing ectoenzymes
such as metalloproteinases [5–7]. In neurological disorders,
CSF analysis is an important tool for diagnosis [4]. Typical
CSF signs of an acute CNS disease include increased CSF
cell count and increased albumin CSF/serum concentration
quotient, the latter indicating an impairment of the blood–
CSF barrier, as albumin is exclusively produced in the liver
and thus can only occur in the CNS by passing the barrier.
Immune reactions in the CNS include an intrathecal anti-
body synthesis of immunoglobulins originating from
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perivascular infiltrates of B-lymphocytes. Beneath the
synthesis of specific antibodies in infectious diseases, the
humoral immune response in the CNS may lead to poly-
specific/unspecific IgG/IgA/IgM patterns. Oligoclonal IgG
detected as oligoclonal bands (OCB) upon isoelectric CSF
focusing with or without corresponding OCB in the serum
reflect an intrathecal humoral immune response with or
without a corresponding systemic immune reaction and is
often seen in autoimmune CNS inflammation including
multiple sclerosis (MS), Sjo¨gren’s syndrome, systemic
lupus erythematosus (SLE), or neurosarcoidosis, but also in
CNS infections [8–10]. Due to an improvement of MRI
techniques, decreasing emphasis is placed on the value of
CSF OCB in the diagnosis and study of MS [11]. Never-
theless, beneath the value of standard CSF analysis for the
exclusion of differential diagnoses, OCB analysis may
provide relevant information in the diagnostic process of
autoimmune diseases. Positive OCB provide direct evi-
dence of immune reactions in the CNS while imaging
provides only indirect information. OCB are present in
approximately 90–95 % of MS patients, and thereby a
positive result supports the diagnosis of MS against, for
example, vascular lesions [12, 13]. Also, within the group
of autoimmune inflammatory diseases, the analysis of OCB
may be helpful for differential diagnoses. For example,
neuromyelitis optica (NMO) may resemble MS. OCB
might be positive in NMO, but much less often than in MS,
and therefore the determination of OCB could be helpful in
distinguishing MS from NMO [14, 15].
CSF analysis is usually performed for diagnostic purposes
and by lumbar puncture (LP). As it is painful and invasive, it
is only performed when clearly indicated. Therefore,
longitudinal data on changes of OCB synthesis during the
clinical course of an autoimmune disease are limited [16–18].
The aim of this study was to examine to what extent OCB
results change intraindividually over time and with which
clinical conditions such changes might be associated.
Methods
Patients
We retrospectively analyzed 17,002 anonymized serial
lumbar punctures documented in the CSF database,
Department of Neurology, University Hospital Zurich,
after pseudonymization. This database includes demo-
graphic (age, gender), clinical (confirmed or suspected
diagnosis), and CSF data from 1992 on. Cases were
included when C2 paired CSF and serum samples were
analyzed for OCB and the diagnosis was documented in the
database.
OCB definitions
OCB were assessed by isoelectric focusing electrophoresis
with anti-human-IgG and silver stain (PhastSystem, GE
Healthcare, Heidelberg, Germany). OCB were identified by
two experienced raters in consensus reading and, in rare
case of differences, by the laboratory supervisor. OCB
negative (OCB neg) was defined as no OCB detection in
CSF and serum (Fig. 1a). OCB positive (OCB pos) was
defined as C1 OCB in the CSF, but no OCB in corre-
sponding serum (Fig. 1a). OCB pos/pos was defined as C1
OCB pos OCB neg
C C
a b
S S
OCB pos/pos
Identic OCB 
in C and S
OCB pos+/pos
*Additional band in CSF
SC
*
C S
Fig. 1 Paired CSF and serum
samples of OCB. a Two sets of
paired CSF (C) and serum
samples (S) showing the
patterns of OCB pos, OCB neg.
b Two sets of paired CSF and
serum sample illustrating the
pattern of OCB pos/pos and
OCB pos?/pos. Isoelectric
focusing electrophoresis with
anti-human-IgG and silver stain.
The lower image quality can be
explained because we work with
microgels that subsequently
were scanned in
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identic OCB in CSF and serum (Fig. 1b). OCB pos?/pos
was defined as identical OCB in CSF and serum plus
additional OCB in the CSF (Fig. 1b).
Results
OCB analyses were done at least twice in 144 patients with
confirmed diagnoses (29 in 115 patients, 39 in 16 patients,
49 in four patients, 59 in two patients, 69 in four patients,
79 in one patient, and 109 in two patients). There was no
change in the result of OCB in 109 cases. In 16 of them,
OCB were analyzed more often than twice, and the results
were also unchanged in those analyses. In 35 cases, OCB
changed over time. In 13 of these cases, OCB were ana-
lyzed more than twice.
The group of patients with stable OCB included 43
women and 66 men. At the date of the first LP, the age of
Table 1 Overview of the change of OCBs
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Autoimmune 62 750 (5-3256) CIDP 3 1+1b; 2 1 1a+1b+2a C1: clinical 
deterioration; C4: 
follow-up, later on, 
multiple sclerosis is 
the additional 
suspected diagnosis 
(suspected diagnosis 
was already made 
when OCBs were 
still negative)
Collagenosis 1 1 1a+1c 1 1a+1c C10 and 11: clinical 
deterioration/ new 
symptoms
GBS 2 2
Morbus 
Behcet
1 1a+1c C6: follow-up
MS 16 
1b+4a,1c+4a
; 6; 1c+4a; 
1c+7; 
1b+4a; 
1c+4a; 1c; 
1c; 1c; 1c
1 5 1 1 3 4a; 
1b+4; 
1b+4a
2 1a+1c; 1a C2: two cases in the 
context of a study, 
C5: diagnosis, C6: 
follow-up/ 
diagnosis; C7: 
follow-up; C11: 
clinical 
deterioration, 
follow-up
CIS 3 3 2 1a+1b C2: follow-up for 
exclusion of 
neuroborreliosis 
(positive serologic 
testing for 
borreliosis); C4: 
follow-up
Mononeuritis 
multiplex
2
Myelitis 2 1c 2 8; 1c+6 1 C4: clinical 
deterioration
Narcolepsy/ 
Cataplexy
2
NMO 1 1b 2 1+1b C4: clinical 
deterioration
Neuro-
sarcoidosis
2 1a+1c; 1c 2 1b; 1a+1b C2: clinical 
deterioration
Paraneoplasm 1 1c 1 1c+2 1 1c C7 and C11: follow-
up
Vasculitis 1 1a+1b
Infectious 27 459 (6-2122) HIV 2 2
Meningitis/ 
Meningo-
encephalitis
3 6 3 1b+6, 3+6 4 1+1b+3, 
6, 6
C1 and C4: follow-
up
Myelo- 3 1b; 1b+6 1 1c C1: new symptoms, 
radiculitis follow-up, C11: 
follow-up (clinical 
improvement)
PML 1 1 1 1 C4: clinical 
deterioration
SSP 2 
Neuro-
borreliosis
2 6; 1c+6 1 1b+6
Neurolues 1 6 1 6 C1 and C2: follow-
up
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Neuro-
degenerative
16 457 (8-2740) Dementia 3 1 1 1 1 C1: follow-up, 
clinical 
deterioration; C6: 
occurrence of an 
autoimmune disease 
at the date of the 
second LP; C8: 
follow-up, JC Virus 
positive at the date 
of 1. LP, negative at 
2. LP
Motor neuron 
disease
1 1
MSA 1
Neuro-
degenerative
3 1a+2 C1: follow-up
Parkinson 1disease
Spinal canal 
stenosis
2
Spino-
cerebellar 
ataxia
1 C6: follow-up
Neuro-
vascular
6 806 (7-2699) Encephalo-
pathy vascular
3 1 C1: follow-up, 
exclusion of NPH
Hemorrhage 1
Ischemia 1
Neuro-
oncological
6 52 (1-138) Lymphoma 
CNS
1 C4: follow-up/ 
diagnosis, clinical 
deterioration
Meningeoma 1
Metastasis/ 
Meningeosis 
carcinomatosa
1 1
Tumour mass 1 1
Others 27 181 
(88-274)
Facial nerve 
paresis
2 1c+6 C2: follow-up, no 
clear clinical 
recovery
550 
(12-1614)
Headache 3 C1: clinical 
deterioration
1052 
(13-2091)
Mitochondrial 
disease
2
1643 Morbus Fahr 1
249 Myelopathy 2
(223-274)
17 Neuro-
psychiatric 
deficit
1
8 NPH 1
1581
(77-3533)
Others 3 3 1 C11: follow-up
2482 PNP 1
1191 
(81-2300)
Pseudotumor 
cerebri
2
779 Restless legs 
Syndrome
1
471 
(24-1541)
Seizure 
disorder
4 C1: another non-
convulsivus status 
epilepticus
CIDP chronic inflammatory demyelinating polyneuropathy, CIS clinically isolated syndrome, GBS Guillain–Barre´ syndrome, MS multiple sclerosis, MSA
multisystem atrophy, NMO neuromyelitis optica device, NPH normal pressure hydrocephalus, PML progressive multifocal leukoencephalopathy, PNP
polyneuropathy, SSP subacute sclerosing panencephalitis
1 Under immunosuppressive therapy
1a Start immunosuppressive therapy between first and second CSF analysis
1b Steroid therapy
1c Steroid therapy between first and second CSF analysis
2 Immunomodulating therapy (IVIG) between first and second CSF analysis
2a Immunomodulating therapy (IVIG) before first CSF analysis
3 Autoimmune disease and immunosuppressive therapy
4 Under immunomodulating therapy (disease modifying therapy)
4a Start immunomodulating therapy (disease modifying therapy) between first and second CSF analysis
5 Under immunomodulating therapy (disease modifying therapy) and immunosuppressive therapy
6 Antiviral therapy/antibiotic therapy
7 Plasmapheresis between first and second CSF analysis
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individuals ranged from 18 to 80 years (median, 44 years),
and at the second one from 18 to 81 years (median,
47 years). The LP were done between April 1999 and July
2010. The time span between the LP ranged from 1 to
3,533 days (median, 241 days). Unchanged OCB neg
appeared in 65 patients with mainly neurodegenerative and
neurovascular diseases or other widespread diagnosis like
headache or epilepsy and particularly without autoimmune
or infectious CNS disease (Table 1, column 1). An intra-
thecal only OCB synthesis (unchanged OCB pos) was
repeatedly found in 41 individuals with mostly autoim-
mune or infectious CNS diseases including MS/clinically
isolated syndrome (CIS), myelitis, neurosarcoidosis, vas-
culitis, HIV, meningitis/meningoencephalitis, and neurol-
ues (Table 1, column 2). A systemic OCB synthesis was
repeatedly observed in three patients; each one with hem-
orrhage, motor neuron disease, and normal pressure
hydrocephalus (unchanged OCB pos/pos).
The group of patients with newly appearing or with
disappearing OCB included 21 women and 14 men
(Table 1, orange and blue columns). At the date of the first
LP the age ranged from 16 to 72 years (median, 51 years)
and at the second one from 21 to 75 years (median,
52 years). The LP were performed between July 1999 and
July 2010. The time span between the LP ranged from 6 to
2,942 days (median, 339 days); in the subgroup with newly
emerging OCB from 6 to 2,942 days (median, 329 days),
and in the group with disappearing OCB from 53 to 1,049
(median, 347 days).
The shift OCB neg ? OCB pos appeared in autoim-
mune, infectious, and neurooncological diseases including
MS/CIS, NMO, chronic inflammatory demyelinating pol-
yneuropathy (CIDP), myelitis, progressive multifocal leu-
koencephalopathy (PML), neuroborreliosis, meningitis/
meningoencephalitis, primary CNS lymphoma. Notewor-
thy, in the patient with CIDP, the additional diagnosis of
possible MS was made between the two LP. The shift OCB
neg ? OCB pos?/pos appeared in one MS patient. The
change OCB neg ? OCB pos/pos occurred in autoimmune
and neurodegenerative diseases (Table 1, column 6). In the
patient with dementia, the diagnosis of an autoimmune
disease (Basedow’s disease) was made in addition at the
time of the second LP. The shift OCB pos ? OCB pos?/
pos appeared in autoimmune diseases including MS and
smoldering lymphoma with paraneoplastic polyradiculo-
neuropathy. The shift OCB pos ? OCB pos/pos was only
seen in one patient with dementia. Finally, the shift OCB
pos/pos ? OCB pos?/pos was only seen in multiple
myeloma with emerging paraneoplastic polyneuropathy.
In the group of patients with a loss of OCB, the shift OCB
pos?/pos ? OCB pos was seen in one patient with autoim-
mune disease (collagenosis, M. Sjo¨gren with CNS involve-
ment). An immunosuppressive therapy with azathioprine had
been established before the second LP. The shift OCB
pos ? OCB neg occurred in autoimmune and infectious
diseases including collagenosis with CNS involvement, MS,
neurosarcoidosis, breast cancer with paraneoplastic sensory
polyneuropathy and leukoencephalopathy of unknown spec-
ification, myeloradiculitis, and PML.
In the patient with myeloradiculitis steroid therapy and
in the patient with collagenosis cyclophosphamide,
hydroxychloroquine and steroids had been started between
LP. Moreover, in the MS patients, immunosuppressive
therapy had been started between LP because of the addi-
tional diagnosis of CIDP and oligoarthritis with positive
lupus serologic testing, respectively. Both patients with
neurosarcoidosis had been treated with steroids between
the LP, one with methotrexate in addition. The patient with
PML suffered from chronic lymphocytic leukemia and had
been treated with several chemotherapies and allogenic
bone marrow transplantation between the two LP.
In all of the 24 MS patients included in our analysis,
OCB were found positive at least once (Table 1, column 2,
4–7 and 11). Of the 24 MS patients, 19 had the diagnosis
relapsing remitting MS (RRMS). In three of these RRMS
patients, OCB were initially negative in the early phase of
disease, but were detected in a subsequent analysis
(Table 2, column 3–5). Eight patients had the diagnosis of
CIS. Each three of them showed and did not show OCB in
both LP (time span, 11–482 and 46–333 days, respec-
tively), two had newly emerging OCB in the second LP
(time span, 329–1,407 days).
Table 2 Overview of the change of OCBs in MS patients
Diagnosis N Time between
CSF analysis (days),
mean (range)
Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 Column 7
Unchanged
OCB neg
Unchanged
OCB pos
OCB neg ?
pos
OCB neg ?
pos?/pos
OCB neg ?
pos/pos
OCB pos ?
pos?/pos
OCB
pos ? neg
RRMS 19 953 (64–3,256) 14 1 1 1 2
PPMS 1 331 1
SPMS 4 852 (26–2,942) 1 1 2
CIS 8 345 (11–1,407) 3 3 2
RRMS relapsing-remitting multiple sclerosis, PPMS primary progressive multiple sclerosis, SPMS secondary progressive multiple sclerosis, CIS
clinically isolated syndrome
558 J Neurol (2014) 261:554–560
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Discussion
Differential diagnoses of diseases associated with CSF IgG
OCB include infections, systemic and CNS inflammatory
disorders, peripheral neuropathies, and others [10, 13, 16,
19–21].
In clinical practice, OCB are often investigated in the
diagnostic work-up of inflammatory CNS disorders, in
particular MS. In our study, OCB were not only observed
in MS patients but also in patients with several other
autoimmune and with infectious CNS diseases, as expec-
ted. However, it is noteworthy that OCB were found
positive at least once in all of 24 MS patients. Time spans
between an initially negative and the second, positive result
ranged from 6.6 to 60 months (mean, 25 months). Thus,
although presence of OCB in the CSF are no longer criteria
for the diagnosis of RRMS and are only a facultative cri-
teria for the diagnosis of primary progressive MS [11], our
data suggest that it might be reasonable to do a second LP
if OCB are negative at first in cases of suspected MS. If
patients continue to have no intrathecal OCB production, it
may become necessary to reconfirm an MS diagnosis.
In one-quarter of patients with repeated OCB analyses,
the OCB result changed over time. A change to a positive
result was often observed in infectious diseases. For
example, in four patients with meningitis or meningo-
encephalitis, OCB where initially negative, but positive in
the second LP 6–1,471 days (mean, 17 days) later, pre-
sumably corresponding to a post-infectious immunological
CNS response.
Changes from a positive towards a negative OCB results
were less frequent, observed in autoimmune disorders
including MS, neurosarcoidosis, and collagenosis as well
as in PML. Interestingly, an immunosuppressive therapy
had been established before the second LP in the patients
with MS and collagenosis and in one of the patients with
neurosarcoidosis (Table 1). These immunosuppressive
therapies may be assumed as the reason for the disap-
pearance of OCB, which is unusual in MS patients [16, 22].
In addition to immunosuppression, the treatment with na-
talizumab can also lead to the disappearance of OCB from
the CSF of MS patients [17, 23]. In accordance, Harrer and
colleagues [23] showed that CSF IgG production is reduced
by natalizumab therapy in MS. Fingolimod treatment also
influences the number of lymphocytes in the CNS in
neuroinflammatory diseases. Kowarik and colleagues [24]
observed that treatment with fingolimod reduces the CSF
leukocyte count in MS patients, but the B cell levels were
more or less unchanged. Consequently, CSF IgG levels and
occurrence of OCB were not influenced. Our data suggest
that immunosuppression reduces B cell activity in the CNS
in MS patients. It is tempting to speculate that a loss of OCB
may be associated with response to immunosuppressive
therapy of autoimmune diseases affecting the CNS. This is
in line with other studies showing that the degree of
humoral CNS immune response may be linked to the
prognosis, i.e., the absence (or disappearance) of OCBs
in MS patients may be associated with a better prognosis
[22].
In five of 19 RRMS patients of our study population,
OCB were initially negative or restricted to the CSF, but
became positive or also detectable in the serum in the
second investigation (Table 2, column 3–6). In one of these
five patients, MS was diagnosed at the time of the second
LP, and in another patient, the MS diagnosis was made
later on. Further, one RRMS patient had initially positive
OCB, became negative during natalizumab treatment, but
positive again at PML onset (already published by Harrer
2013 [23]). This is in line with the observation of a switch
from negative to positive OCB in another patient at PML
onset (Table 1, column 4) as well as stable positive OCB in
a patient with known PML suffering from HIV (Table 1,
column 2). In the same context, Mazzarello et al. [25]
found positive OCB in patients with PML.
In conclusion, the analysis of CSF OCB still plays an
important role in the diagnostic process of autoimmune
diseases affecting the CNS, particularly MS. OCB results
may change over time, which can be explained by clinical
conditions. Such variability must be taken into account for
the interpretation of OCB results.
Limitations of our study are the retrospective analysis of
data and the small number of cases per diagnosis. Fur-
thermore, the second or further lumbar punctures were
usually done for new clinical situations or for verification
of uncertain diagnoses, which leads to selection bias
favoring a higher amount of patients with changes in the
OCB status.
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